Gender Disparity in Post Heart Attack Treatment

CAITLIN WILLIAMS | July 29, 2018

article image
Every 40 seconds, someone in the United States has a heart attack, with 790,000 Americans having a heart attack every year. After a heart attack, heart damage can affect heart rhythm, pumping action, and blood circulation. Damage can increase the risk of another heart attack or other conditions such as stroke and kidney disorders. A recent study published in the Medical Journal of Australia showed a gender disparity in treatment after a heart attack, leading to increased death rates and adverse cardiovascular events in women compared to men.

Spotlight

Redirect Health

Redirect Health provides businesses with affordable healthcare plans using a partial self-insurance model that comply with the Affordable Care Act, reduce administration costs associated with traditional insurance plans, and enhance the employee’s healthcare experience.

OTHER ARTICLES

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 26, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | March 26, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | March 26, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Spotlight

Redirect Health

Redirect Health provides businesses with affordable healthcare plans using a partial self-insurance model that comply with the Affordable Care Act, reduce administration costs associated with traditional insurance plans, and enhance the employee’s healthcare experience.

Events